论文部分内容阅读
通过血管紧张素转换酶(angiotensin-converting enzyme,ACE)抑制作用,阻断从血管紧张素Ⅰ至血管紧张素Ⅱ的转换过程,已证实对不同类型的高血压有很好疗效。MK-521是一种新的不含巯基的口服ACE抑制剂。作者研究了10例轻至中度原发性高血压患者,8例男性,2例女性,平均年龄51岁,未经治疗的立位舒张压为95～115mmHg,在整个研究期间应用150mEq钠和80mEq钾的饮食。作者评价了MK-521、双氢氯噻嗪和两者合用对血压、心率、血管紧张素转换酶活性、血浆肾素活性和血浆醛固酮浓度的作用。
The conversion of angiotensin I to angiotensin II is blocked by angiotensin-converting enzyme (ACE) inhibition and it has been shown to be effective in treating various types of hypertension. MK-521 is a novel, non-sulfhydryl-based oral ACE inhibitor. The authors studied 10 patients with mild-to-moderate essential hypertension, 8 males and 2 females, mean age 51 years. Untreated orthostatic diastolic pressure was 95-115 mmHg. During the study period 150 mEq of sodium and 80mEq potassium diet. The authors evaluated the effects of combination of MK-521, hydrochlorothiazide, and both on blood pressure, heart rate, angiotensin-converting enzyme activity, plasma renin activity, and plasma aldosterone concentration.